Evidence map›Paper›PMID 41413138›Full record

Trial reportScientific reports2025

Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial).

Saran Sukkamolsantiporn, Phubordee Bongkotvirawan, Soonthorn Chonprasertsuk, Bubpha Pornthisarn, Sith Siramolpiwat, Patommatat Bhanthumkomol, Navapan Issariyakulkarn, Pornpen Gamnarai, Arti Wongcha-Um, Natsuda Aumpan and 7 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Saran Sukkamolsantiporn *Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Phubordee Bongkotvirawan *Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Soonthorn ChonprasertsukCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Bubpha PornthisarnCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Sith SiramolpiwatCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Patommatat BhanthumkomolCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Navapan IssariyakulkarnCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Pornpen GamnaraiCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Arti Wongcha-UmCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Natsuda AumpanCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand.
Virunpat VilaichoneChulabhorn International College of Medicine (CICM) at Thammasat University, Bangkok, 12120, Pathum Thani, Thailand.
Phornphan SornchuerDepartment of Preclinical Science, Faculty of Medicine, Thammasat University, Bangkok, 12120, Pathum Thani, Thailand.
Varocha MahachaiChulabhorn International College of Medicine (CICM) at Thammasat University, Bangkok, 12120, Pathum Thani, Thailand.
Muhammad MiftahussururDivision of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Yoshio YamaokaDepartment of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, Yufu, Japan.
Peerapong KitipawongChulabhorn International College of Medicine (CICM) at Thammasat University, Bangkok, 12120, Pathum Thani, Thailand.
Ratha-Korn VilaichoneCenter of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, 12120, Pathum Thani, Bangkok, Thailand. Vilaichone@hotmail.co.th.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vonoprazan, a novel and potent acid suppressant, has recently been incorporated into Helicobacter pylori eradication regimens. However, the data on combination of vonoprazan with levofloxacin remains scarce. This study represents one of the first evaluations comparing 7-day and 14-day once-daily regimens containing vonoprazan, levofloxacin, clarithromycin-MR, and bismuth for H. pylori eradication in regions characterized by high clarithromycin and metronidazole resistance. Between March 2022 and December 2023, patients presenting with dyspepsia who underwent upper gastrointestinal endoscopy at a tertiary care hospital in Thailand were recruited. Those testing positive for H. pylori infection were randomly assigned to receive either a 7-day or 14-day once-daily regimen comprising vonoprazan 40 mg, clarithromycin-MR 1 g, levofloxacin 500 mg, and bismuth subsalicylate 1,048 mg. CYP3A4 polymorphism testing and antimicrobial susceptibility assessment (using either the Epsilometer test or the GenoType

Indexed as

Anti-Bacterial AgentsClarithromycinDrug Resistance, BacterialHelicobacter InfectionsHelicobacter pyloriPyrrolesSulfonamidesAdultAgedBismuthDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansLevofloxacinMale1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAnti-Bacterial AgentsBismuthClarithromycinLevofloxacinProton Pump InhibitorsPyrrolesSulfonamides

Identifiers

PMID41413138
PMCPMC12714860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.